A study on cartilage oligomeric matrix protein gene expression in patients suffering from osteoarthritis of knee treated with Rhus toxicodendron 200th potency - NI

Self0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•1.Patients with frequent knee symptoms in the past three months defined as pain, aching or stiffness in or around the knee on most days ? for at least one month during the past three months.
•2.Overweight or have two or more other eligibility risk factors
•The specific eligibility risk factor criteria for the incidence will be
•Frequent knee symptoms.
•Frequent use of medication on most days of a month in the past 12 months.
•Radiographic OA compared to knee without symptoms.
•Knee injury, defined as a history of knee injury causing difficulty walking for atleast a week.
•3.Age group: 35 to 80 yrs.
•4.Sex: Both Males and Females.
•5.Patients with symptomatology of Rhus toxicodendron

•1.Patients suffering from other severe systemic diseases.
•2.Age group: Below 35 yrs. and above 80 yrs.
•3.Patients with symptoms of medicines other than Rhus toxicodendron.
•4.Bilateral total knee joint replacement or plans to have bilateral knee replacement in the next 3 years.
•5.Pregnancy
•6.Unwilling to sign informed consent.

发起方